Proshares Trust (ZBIO) Total Non-Current Liabilities (2023 - 2025)
Historic Total Non-Current Liabilities for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $73.2 million.
- Zenas BioPharma's Total Non-Current Liabilities changed N/A to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year change of. This contributed to the annual value of $218000.0 for FY2024, which is 9907.29% down from last year.
- Per Zenas BioPharma's latest filing, its Total Non-Current Liabilities stood at $73.2 million for Q3 2025.
- In the past 5 years, Zenas BioPharma's Total Non-Current Liabilities ranged from a high of $73.2 million in Q3 2025 and a low of $218000.0 during Q4 2024
- Over the past 3 years, Zenas BioPharma's median Total Non-Current Liabilities value was $23.5 million (recorded in 2023), while the average stood at $32.3 million.
- The largest annual percentage gain for Zenas BioPharma's Total Non-Current Liabilities in the last 5 years was 9907.29% (2024), contrasted with its biggest fall of 9907.29% (2024).
- Over the past 3 years, Zenas BioPharma's Total Non-Current Liabilities (Quarter) stood at $23.5 million in 2023, then plummeted by 99.07% to $218000.0 in 2024, then surged by 33463.76% to $73.2 million in 2025.
- Its Total Non-Current Liabilities stands at $73.2 million for Q3 2025, versus $218000.0 for Q4 2024 and $23.5 million for Q4 2023.